Modus Therapeutics
Modus Therapeutics Secures Bridge Financing from Karolinska Development
STOCKHOLM, SWEDEN – March 31 2025: Modus Therapeutics Holding AB (“Modus”) today announces that the company has secured access to bridge financing of up to SEK 5.0 million from its largest shareholder, Karolinska Development AB. The financing enables Modus to maintain strong operational momentum in its ongoing Phase IIa study targeting anemia in chronic kidney disease (CKD).
John Öhd, CEO of Modus Therapeutics, commented:
“We are grateful for the continued support from our long-term investor Karolinska Development. This bridge financing is an important step in ensuring the progress of our clinical program, with current focus on completing Part 1 of our Phase IIa CKD study and preparing for Part 2. In parallel, we continue to actively evaluate options for long-term financing.”
Datum | 2025-03-31, kl 14:00 |
Källa | MFN |
